Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...

Catalyst Pharmaceutical (CPRX) closed the last trading session at $24.96, gaining 0.5% over the past four weeks, but there ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model ...

CPRX is a #2 (Buy) on the Zacks Rank, with a VGM Score of A. Additionally, the company could be a top pick for growth investors. CPRX has a Growth Style Score of B, forecasting year-over-year ...

Catalyst Pharmaceuticals (NasdaqCM:CPRX) recently announced the appointment of William T. Andrews, MD, as Chief Medical Officer, a move that coincides with a 13% rise in the company's share price over ...

FIRDAPSE boosts Catalyst's strong Q1 2025 results, beating forecasts. With 15–20% growth projected, see why analysts rate ...

This was the stock's second consecutive day of gains.

Today we look at two noteworthy recent insider buys. At Catalyst Pharmaceuticals (CPRX), a filing with the SEC revealed that on Tuesday, Director Charles B. O'keeffe bought 20,000 shares of CPRX ...

The stock's fall snapped a two-day winning streak.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Neurocrine Biosciences (NBIX). But which of these two stocks is more ...